Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological Outcome
Low-EPI
2 other identifiers
interventional
4,336
1 country
26
Brief Summary
This study will test whether a lower dose of epinephrine (0.5 mg) given during emergency treatment for out-of-hospital cardiac arrest helps more patients survive with good brain function, compared to the standard dose (1 mg). Adults who experience cardiac arrest outside the hospital and are treated by emergency medical teams will be randomly assigned to receive either the low dose or the standard dose of epinephrine. The study will compare survival and neurological outcomes between the two groups over 28 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jun 2026
Typical duration for phase_3
26 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 9, 2026
CompletedFirst Posted
Study publicly available on registry
March 2, 2026
CompletedStudy Start
First participant enrolled
June 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2030
March 2, 2026
February 1, 2026
4.1 years
February 9, 2026
February 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Modified Rankin Scale (mRS) score
The mRS score is a validated score measuring neurologic outcomes after cardio-pulmonary resuscitation (CPR) : * mRS 0. No symptoms. * mRS 1. No significant disability. Able to perform all usual activities, despite some symptoms. * mRS 2. Slight disability. Independent but unable to perform usual activities (work, sports, leisure). mRS 3. Moderate disability. Requires assistance, but able to walk alone. * mRS 4. Moderately severe disability. Walking assistance and daily living activities not possible. mRS 5. Major disability. Bedridden, incontinent and requires constant nursing care and attention. * mRS 6. Death.
28-day
Secondary Outcomes (4)
Return of Spontaneous Circulation (ROSC).
Periprocedural period of cardiopulmonary resuscitation
Vital status
Periprocedural period of cardiopulmonary resuscitation
vital status
28 days post-cardiac arrest
Modified Rankin Scale (mRS) score.
28 days post-cardiac arrest
Study Arms (2)
Epinephrine 0.5 mg intravenous bolus every 3-5 minutes during Cardio-Pulmonary Resuscitation
EXPERIMENTALEpinephrine 0.5 mg intravenous bolus every 3-5 minutes during Cardio-Pulmonary Resuscitation
Epinephrine 1 mg IV bolus every 3-5 minutes during Cardio-Pulmonary Resuscitation
ACTIVE COMPARATOREpinephrine 1 mg intravenous bolus every 3-5 minutes during Cardio-Pulmonary Resuscitation
Interventions
Epinephrine 0.5 mg/mL solution for injection, administered as a 0.5 mg intravenous bolus every 3 to 5 minutes during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest. T
Epinephrine 1 mg/mL solution for injection, administered as a 1 mg intravenous bolus every 3 to 5 minutes during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest.
Eligibility Criteria
You may qualify if:
- Male or female, aged ≥18 years. Out-of-hospital cardiac arrest for which resuscitation is decided by the SMUR team.
- Medical Out-of-hospital cardiac arrest. Affiliated with or beneficiary of a social security plan
You may not qualify if:
- Non-medical Out-of-hospital cardiac arrest (traumatic, drownings, electrocution, asphyxia, overdose, unknown cause).
- Out-of-hospital cardiac arrest without advanced life support (Do Not Attempt Resuscitation order, body finding, the decision not to attempt advanced life support is at the physician's discretion).
- Pregnant women, birthing or breastfeeding mothers
- Adults under legal protection measure (such as guardianship, conservatorship)
- Individuals deprived of liberty due to judicial or administrative decision
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (26)
CH Annecy
Annecy, France
Centre hospitalier de la Côte Basque
Bayonne, France
CHU Besancon
Besançon, France
CHU Brest
Brest, France
CHU Colmar
Colmar, France
CH SUD Francilien
Corbeil-Essonnes, France
Brigade de Sapeurs-Pompiers de Paris
Courbevoie, France
Centre Hospitalier Universitaire Grenoble Alpes
La Tronche, France
Hospices Civils De Lyon
Lyon, France
CHU Montpellier
Montpellier, France
CHRU Nancy
Nancy, France
Centre Hospitalier Universitaire De Nantes
Nantes, France
CHU Nice
Nice, France
CHU Nimes
Nîmes, France
AP-HP Hôpital Necker
Paris, France
Hopital Beaujon
Paris, France
hôpital Lariboisière
Paris, France
La Pitié Salpêtrière
Paris, France
Raymond Poincaré Hospital
Paris, France
CHU Poitiers
Poitiers, France
Centre Hospitalier Universitaire Reims
Reims, France
CHU Rennes
Rennes, France
CHU Rouen
Rouen, France
Centre hospitalier Annecy Genevois Site Julien en GENEVOIS
Saint-Julien-en-Genevois, France
Centre Hospitalier Universitaire De Toulouse
Toulouse, France
CHU Tours
Tours, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Coordinating Investigator
Study Record Dates
First Submitted
February 9, 2026
First Posted
March 2, 2026
Study Start
June 1, 2026
Primary Completion (Estimated)
July 1, 2030
Study Completion (Estimated)
July 1, 2030
Last Updated
March 2, 2026
Record last verified: 2026-02